Lucid Diagnostics LUCD Stock
Lucid Diagnostics Price Chart
Lucid Diagnostics LUCD Financial and Trading Overview
| Lucid Diagnostics stock price | 1.01 USD |
| Previous Close | 1.03 USD |
| Open | 1.03 USD |
| Bid | 0.74 USD x 200 |
| Ask | 1.29 USD x 200 |
| Day's Range | 1 - 1.05 USD |
| 52 Week Range | 0.9 - 1.63 USD |
| Volume | 885.53K USD |
| Avg. Volume | 810.84K USD |
| Market Cap | 196.48M USD |
| Beta (5Y Monthly) | 1.104 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.34 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.9 USD |
LUCD Valuation Measures
| Enterprise Value | 204.06M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.885714 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 38.27033 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 39.747 |
| Enterprise Value/EBITDA | -4.217 |
Trading Information
Lucid Diagnostics Stock Price History
| Beta (5Y Monthly) | 1.104 |
| 52-Week Change | -17.26% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 1.63 USD |
| 52 Week Low | 0.9 USD |
| 50-Day Moving Average | 1.12 USD |
| 200-Day Moving Average | 1.16 USD |
LUCD Share Statistics
| Avg. Volume (3 month) | 810.84K USD |
| Avg. Daily Volume (10-Days) | 1.1M USD |
| Shares Outstanding | 190.76M |
| Float | 140.58M |
| Short Ratio | 6.95 |
| % Held by Insiders | 26.52% |
| % Held by Institutions | 19.37% |
| Shares Short | 6.62M |
| Short % of Float | 4.29% |
| Short % of Shares Outstanding | 3.47% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -964.49% |
| Gross Margin | -31.35% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -92.087% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 5.13M USD |
| Revenue Per Share (ttm) | 0.04 USD |
| Quarterly Revenue Growth (yoy) | 51.70% |
| Gross Profit (ttm) | -1610000 USD |
| EBITDA | -48394000 USD |
| Net Income Avi to Common (ttm) | -58179000 USD |
| Diluted EPS (ttm) | -0.34 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 29.37M USD |
| Total Cash Per Share (mrq) | 0.15 USD |
| Total Debt (mrq) | 26.8M USD |
| Total Debt/Equity (mrq) | 670.08 USD |
| Current Ratio (mrq) | 1.067 |
| Book Value Per Share (mrq) | -0.037 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -46121000 USD |
| Levered Free Cash Flow (ttm) | -25522750 USD |
Profile of Lucid Diagnostics
| Country | United States |
| State | NY |
| City | New York |
| Address | 360 Madison Avenue |
| ZIP | 10017 |
| Phone | 917 813 1828 |
| Website | https://www.luciddx.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 82 |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Q&A For Lucid Diagnostics Stock
What is a current LUCD stock price?
Lucid Diagnostics LUCD stock price today per share is 1.01 USD.
How to purchase Lucid Diagnostics stock?
You can buy LUCD shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lucid Diagnostics?
The stock symbol or ticker of Lucid Diagnostics is LUCD.
Which industry does the Lucid Diagnostics company belong to?
The Lucid Diagnostics industry is Medical Devices.
How many shares does Lucid Diagnostics have in circulation?
The max supply of Lucid Diagnostics shares is 190.76M.
What is Lucid Diagnostics Price to Earnings Ratio (PE Ratio)?
Lucid Diagnostics PE Ratio is now.
What was Lucid Diagnostics earnings per share over the trailing 12 months (TTM)?
Lucid Diagnostics EPS is -0.34 USD over the trailing 12 months.
Which sector does the Lucid Diagnostics company belong to?
The Lucid Diagnostics sector is Healthcare.
Lucid Diagnostics LUCD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}